Skip to content
Sonic
AI
Sonic
AI
Home
Discover
Ask Sonic
Projects
Use with Claude or ChatGPT
Show me around
Request source or feature
Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery, Sonic AI
Home
/
The Long Run
/
Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery
The Long Run
Notify me
•
Apr 7, 2026
•
1:16:43
Interview
Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery
From
The Long Run
Abbas Kazimi
(CEO, Nimbus Therapeutics, guest)
Get the full transcript next time The Long Run releases an episode
Summary, key quotes, top claims, and the searchable transcript — emailed automatically. No card needed.
Sign up
Executive Summary
Nimbus Therapeutics has pioneered a capital-efficient biotech model, using a lean team, virtual R&D, and a unique LLC/C-corp structure to develop and monetize high-value assets.
The company's strategy was validated by the $4 billion upfront sale of its TYK2 inhibitor, zazocytinib, to Takeda, which is now poised to become a multi-billion dollar blockbuster for autoimmune diseases.
Nimbus employs a rigorous portfolio strategy, terminating 75% of its programs to recycle capital into the most promising assets, such as its current WRN (cancer) and SIK2 (immune disorders) inhibitors.
The company's drug discovery approach is rooted in computational chemistry and structure-based design, viewing technology and AI not as an 'answer engine' but as a 'thinking amplifier' to augment human expertise.
Continue your research
Keep pulling the thread on Abbas Kazimi.
Capital-Efficient Biotech Model
Strategic Asset Monetization
Computationally-Driven Drug Discovery
Or ask anything across 400+ expert conversations
12
quotes
Transcript
Key Arguments
Analysis
Quotes & Entities
12
Related
Loading transcript...
Processed May 4, 2026
Daily intelligence brief →
yt-dlp + mlx-whisper + Gemini